Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1Genitourinary 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Rectal Neoplasms 1Camurati-Engelmann Syndrome 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × LY-2157299 × Gastrointestinal × Clear all
NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Providence Health & Services

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
204 enrolled 27 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡